Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now.
Neurocrine Biosciences, Inc. is one of the most oversold stocks.
TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management’s 2026 projection, and the company’s fourth-quarter results were included in the firm’s financial model.
Neurocrine Biosciences, Inc. announced its fourth-quarter and full-year 2025 financial results earlier on February 11, which show strong top-line growth. According to the report, overall net product sales increased by 29% and 22% year over year to $798.3 million in Q4 and $2.83 billion for the entire year, respectively.
INGREZZA generated $657.5 million in fourth-quarter sales and $2.51 billion for the full year, reflecting 7% and 9% annual growth, which is supported by strong prescription demand but partially offset by lower net pricing tied to formulary access investments. Additionally, the report also shows that CRENESSITY contributed $135.3 million in Q4 sales and $301.2 million for the year, which is driven by robust patient enrollment and reimbursement coverage.
Neurocrine Biosciences, Inc. is a biopharmaceutical company developing treatments for neurological and endocrine-related disorders, focusing on innovative therapies for conditions like movement disorders, epilepsy, and hormonal diseases.
READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
